<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6993">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00965718</url>
  </required_header>
  <id_info>
    <org_study_id>ILC-IIT-01</org_study_id>
    <nct_id>NCT00965718</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Activated T-lymphocyte (&quot;Immuncell-LC&quot;) Cell Therapy in Gemcitabine Refractory Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Cell Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Cell Corporation</source>
  <oversight_info>
    <authority>Korea: The Minitry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 Clinical trial to Evaluate the efficacy and safety of activated T-lymphocyte
      (&quot;Immuncell-LC&quot;) cell therapy in Gemcitabine refractory advanced pancreatic cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was designed as a single-center, single group clinical trial, and subjects include
      patients with pathologically-confirmed Gemcitabine refractory advanced pancreatic cancer.

      If subjects agree to participate in the clinical trial by signing a written consent, only
      appropriate subjects, who meet the criteria on the examinations and tests, will undergo this
      clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml
      should be withdrawn to make a study drug at least 2 weeks before administration. Subjects
      should visit to hospital according to the protocol and receive a study drug. Therapeutic
      response rate, overall survival rate, time to progression and the quality of life should be
      investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Every 2 months from the baseline, up to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Disease control rate is defined as the number of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1). Complete Response: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to &lt;10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
Disease control rate = CR or PR or SD patients / ITT population *100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stable Disease(SD)</measure>
    <time_frame>Every 2 months from the baseline, up to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Of the 16 patients in the ITT population, stable disease(SD) was confirmed. Disease control rate was calculated based on the number of CR or PR or SD patients in the ITT population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progressive Disease(PD)</measure>
    <time_frame>Every 2 months from the baseline, up to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Of the 16 patients in the ITT population, progressive disease (PD) was confirmed. Disease control rate was calculated based on the number of CR or PR or SD patients in the ITT population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Every visit, up to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>OS was calculated from the date of enrollment until death from any cause. And OS was estimated using Kaplan-Meier methods with 95% confidence intervals (CIs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Every 2 months from the baseline, up to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Unequivocal progression of existing non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) Assessed Using the Quality of Life Questionnaire Core 30 (QLQ-C30)</measure>
    <time_frame>Every one month from the baseline, up to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QLQ-C30 constitutes a functional scale(physical, role, emotional, cognitive, and social functioning), symptom scores scale(fatigue, nausea/vomiting, pain, dyspnea, constipation, diarrhea, insomnia, appetite loss, financial difficulties), and global QoL scale. With the scores of all scales ranging from 0 to 100, a higher score indicates a better functional scale and a better global QoL scale as well as a worse symptom scores scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) Assessed Using Quality of Life Questionnaire Core 30(QLQ-C30) in Patients With Pancreatic Cancer(QLQ-PAN26 Questionnaire)</measure>
    <time_frame>Every one month from the baseline, up to 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QLQ-PAN26 consists of questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100; higher scores= greater degree of symptoms or treatment side effects and emotional issues.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>activated T lymphocyte</intervention_name>
    <description>intravenous dripping of 200 ml (109~2 1010 lymphocytes/60 kg adult) for 1 hour.</description>
    <other_name>Immuncell-LC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject who signed the written consent form by themselves, protectors or legal
             representatives prior to the clinical trial after the person in charge explained
             fully about objectives, procedure and the characteristics of the study drug.

          2. Patient aged 18 to 75

          3. Patient with pathologically-confirmed, advanced pancreatic cancer

          4. ECOG scale (ECOG-PS) â‰¤2 (Appendix 4. Performance status scale/score)

          5. Patient with anticipated survival period of more than 3 months

          6. Patient with progressed disease after Gemcitabine-based primary anti-cancer
             chemotherapy

          7. Patient whose blood test, renal function test and liver function test results meet
             the following conditions.

        Exclusion Criteria:

          1. Patient with the medical history of immunodeficiency or autoimmune disease that could
             be aggravated by immunotherapy (examples: rheumatoid arthritis, systemic lupus
             erythematosus, vasculitis, multiple sclerosis, adolescent Insulin-Dependent Diabetes
             Mellitus, etc.)

          2. Confirmed immunodeficient patient

          3. Patient with the history of cancer other than skin cancer, local prostate cancer or
             carcinoma in situ of cervix within the last 5 years of the start of study

          4. Patient who has received systemic anti-angiogenic agent

          5. Patient who has received a chemotherapy other than Gemcitabine based chemotherapy

          6. Obvious myocardial failure or uncontrolled arterial hypertension

          7. Patient who has experienced serious allergy (judged by the investigator)

          8. Patient with serious psychological disease (judged by the investigator)

          9. Pregnant woman, breast-feeding woman or woman who want to be pregnant during the
             trial period

         10. Patient who has participated in another clinical trial within the last 4 weeks of the
             start of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siyoung Song, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24916038</url>
    <description>Research paper</description>
  </link>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 16, 2014</lastchanged_date>
  <firstreceived_date>August 24, 2009</firstreceived_date>
  <firstreceived_results_date>June 25, 2014</firstreceived_results_date>
  <responsible_party>
    <name_title>Siyoung Song</name_title>
    <organization>Yonsei university college of medicine</organization>
  </responsible_party>
  <keyword>advanced pancreatic cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with advanced pancreatic cancer who showed disease progression during gemcitabine-based chemotherapy were enrolled in this study.
Twenty patients were enrolled between September 2009 and September 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Immuncell-LC Group</title>
          <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Immuncell-LC Group</title>
          <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="59.2" lower_limit="41" upper_limit="69"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>ECOG-PS</title>
          <description>Eastern Cooperative Oncology Group performance status (ECOG-PS) is used by researchers to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.
&quot;0&quot;-Fully active, able to carry on all pre-disease performance without restriction &quot;1&quot;-Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature &quot;2&quot;-Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>0</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>1</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Duration since diagnosis</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.2" lower_limit="3.8" upper_limit="94.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Period of prior chemotherapy</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5.2" lower_limit="2.0" upper_limit="13.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Site of metastasis</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Liver</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Lung</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Lymph node</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Control Rate</title>
        <description>Disease control rate is defined as the number of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1). Complete Response: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to &lt;10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
Disease control rate = CR or PR or SD patients / ITT population *100</description>
        <time_frame>Every 2 months from the baseline, up to 16 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Patients who underwent response evaluation at least once were included in the intention-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Immuncell-LC Group</title>
            <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Disease Control Rate</title>
            <description>Disease control rate is defined as the number of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1). Complete Response: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to &lt;10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
Disease control rate = CR or PR or SD patients / ITT population *100</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25" lower_limit="3.78" upper_limit="46.22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was calculated from the date of enrollment until death from any cause. And OS was estimated using Kaplan-Meier methods with 95% confidence intervals (CIs).</description>
        <time_frame>Every visit, up to 16 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Patients who underwent response evaluation at least once were included in the intention-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Immuncell-LC Group</title>
            <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival (OS)</title>
            <description>OS was calculated from the date of enrollment until death from any cause. And OS was estimated using Kaplan-Meier methods with 95% confidence intervals (CIs).</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26.6" lower_limit="8.6" upper_limit="44.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Unequivocal progression of existing non-target lesions.</description>
        <time_frame>Every 2 months from the baseline, up to 16 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Patients who underwent response evaluation at least once were included in the intention-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Immuncell-LC Group</title>
            <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Progression</title>
            <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Unequivocal progression of existing non-target lesions.</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11" lower_limit="8.8" upper_limit="13.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QoL) Assessed Using the Quality of Life Questionnaire Core 30 (QLQ-C30)</title>
        <description>QLQ-C30 constitutes a functional scale(physical, role, emotional, cognitive, and social functioning), symptom scores scale(fatigue, nausea/vomiting, pain, dyspnea, constipation, diarrhea, insomnia, appetite loss, financial difficulties), and global QoL scale. With the scores of all scales ranging from 0 to 100, a higher score indicates a better functional scale and a better global QoL scale as well as a worse symptom scores scale.</description>
        <time_frame>Every one month from the baseline, up to 16 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Patients who underwent response evaluation at least once were included in the intention-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Immuncell-LC Group</title>
            <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Quality of Life (QoL) Assessed Using the Quality of Life Questionnaire Core 30 (QLQ-C30)</title>
            <description>QLQ-C30 constitutes a functional scale(physical, role, emotional, cognitive, and social functioning), symptom scores scale(fatigue, nausea/vomiting, pain, dyspnea, constipation, diarrhea, insomnia, appetite loss, financial difficulties), and global QoL scale. With the scores of all scales ranging from 0 to 100, a higher score indicates a better functional scale and a better global QoL scale as well as a worse symptom scores scale.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Global health status at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53.65" spread="29.81" lower_limit="0.76" upper_limit="5.62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Global health status at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40.63" spread="25.98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical functioning at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73.75" spread="30.64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Physical functioning at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="69.58" spread="21.63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role functioning at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.04" spread="32.76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role functioning at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59.38" spread="29.79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emotional functioning at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70.31" spread="20.41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emotional functioning at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61.98" spread="23.56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cognitive functioning at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71.88" spread="24.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cognitive functioning at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68.75" spread="28.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social functioning at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68.75" spread="20.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social functioning at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55.21" spread="27.02"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40.97" spread="24.59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.69" spread="29.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea/vomiting at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.63" spread="25.44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea/vomiting at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.67" spread="18.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.83" spread="25.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.83" spread="26.87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnea at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.42" spread="20.07"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnea at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.08" spread="32.70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.67" spread="24.34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.17" spread="40.14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.33" spread="25.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.33" spread="19.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insomnia at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.58" spread="20.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insomnia at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.75" spread="33.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Appetite loss at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31.25" spread="33.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Appetite loss at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.75" spread="37.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Financial difficulties at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.08" spread="30.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Financial difficulties at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31.25" spread="33.26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.123</p_value>
            <p_value_desc>Global health status scores at baseline and final observation point were compared via a 2-sided t-test.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QoL) Assessed Using Quality of Life Questionnaire Core 30(QLQ-C30) in Patients With Pancreatic Cancer(QLQ-PAN26 Questionnaire)</title>
        <description>QLQ-PAN26 consists of questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100; higher scores= greater degree of symptoms or treatment side effects and emotional issues.</description>
        <time_frame>Every one month from the baseline, up to 16 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Patients who underwent response evaluation at least once were included in the intention-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Immuncell-LC Group</title>
            <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Quality of Life (QoL) Assessed Using Quality of Life Questionnaire Core 30(QLQ-C30) in Patients With Pancreatic Cancer(QLQ-PAN26 Questionnaire)</title>
            <description>QLQ-PAN26 consists of questions (Qs) relating to disease symptoms, treatment (Tx) side effects and emotional issues specific to pancreatic cancer (PC). Questions include on altered bowel habits, pain, dietary changes, disease and Tx-related symptoms and issues related to the emotional and social well-being of participants with PC. All Qs are answered on 4-point Likert scale ranging from '1=not at all' to 4='very much' and subsequently transformed into scales that range from 0-100; higher scores= greater degree of symptoms or treatment side effects and emotional issues.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pancreatic pain at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77.08" spread="23.07"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pancreatic pain at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60.42" spread="25.91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78.13" spread="29.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63.54" spread="29.32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Jaundice at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93.75" spread="11.98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Jaundice at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87.50" spread="16.67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body image at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.25" spread="38.91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body image at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.25" spread="29.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Altered bowel habit at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79.17" spread="24.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Altered bowel habit at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61.46" spread="24.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Health satisfaction at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35.42" spread="24.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Health satisfaction at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34.38" spread="27.53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sexuality scale at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55.21" spread="39.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sexuality scale at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54.17" spread="34.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bloated abdomen at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35.42" spread="25.73"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bloated abdomen at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54.17" spread="34.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Taste changes at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.17" spread="29.50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Taste changes at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.75" spread="35.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indigestion at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.08" spread="34.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indigestion at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41.67" spread="31.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flatulence at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.83" spread="23.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flatulence at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.33" spread="32.20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Weight loss at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.92" spread="33.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Weight loss at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.08" spread="25.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Decreased muscle strength at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31.25" spread="30.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Decreased muscle strength at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.75" spread="29.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dry mouth at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.00" spread="31.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dry mouth at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.83" spread="34.16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment side effects at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.17" spread="36.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment side effects at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39.58" spread="30.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fear for future health at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.08" spread="29.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fear for future health at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58.33" spread="19.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ability to plan ahead at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31.25" spread="33.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ability to plan ahead at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.08" spread="27.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Average pain at baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.13" spread="1.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Average pain at last visit</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.19" spread="2.43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stable Disease(SD)</title>
        <description>Of the 16 patients in the ITT population, stable disease(SD) was confirmed. Disease control rate was calculated based on the number of CR or PR or SD patients in the ITT population.</description>
        <time_frame>Every 2 months from the baseline, up to 16 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Patients who underwent response evaluation at least once were included in the intention-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Immuncell-LC Group</title>
            <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Stable Disease(SD)</title>
            <description>Of the 16 patients in the ITT population, stable disease(SD) was confirmed. Disease control rate was calculated based on the number of CR or PR or SD patients in the ITT population.</description>
            <units>number of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progressive Disease(PD)</title>
        <description>Of the 16 patients in the ITT population, progressive disease (PD) was confirmed. Disease control rate was calculated based on the number of CR or PR or SD patients in the ITT population.</description>
        <time_frame>Every 2 months from the baseline, up to 16 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Patients who underwent response evaluation at least once were included in the intention-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Immuncell-LC Group</title>
            <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progressive Disease(PD)</title>
            <description>Of the 16 patients in the ITT population, progressive disease (PD) was confirmed. Disease control rate was calculated based on the number of CR or PR or SD patients in the ITT population.</description>
            <units>number of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Adverse events were recorded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Immuncell-LC Group</title>
          <description>Activated T lymphocyte, intravenous dripping of 200ml (10^9~2*10^10 lymphocytes / 60kg adult) for 1 hour.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Regarded as definitely not related to therapy by investigators.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ascite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Moonjae Chung, MD</name_or_title>
      <organization>Yonsei university</organization>
      <phone>82-2-2228-2274</phone>
      <email>MJCHUNG@yuhs.ac</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
